adcetris
FDA Approves Adcetris With Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma
The FDA has approved brentuximab vedotin (Adcetris, Seagen, a subsidiary of Pfizer) in combination with ...
FEBRUARY 19, 2025
Nivolumab Substituted for Brentuximab Vedotin in Hodgkin Therapy Improves Outcomes
In older patients with advanced-stage classic Hodgkin lymphoma (cHL), outcomes are particularly improved with lower ...
FEBRUARY 21, 2024
ECHELON-1: BV + Chemo New First-Line Standard for Advanced cHL
Brentuximab vedotin combined with AVD chemotherapy is the first regimen to demonstrate improved OS versus ...
DECEMBER 7, 2022
Adcetris Now Indicated to Treat Classic Hodgkin Lymphoma
The FDA approved brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy for the ...
MARCH 22, 2018
BV + Bendamustine May Be Effective for Primary Refractory HL
The combination of brentuximab vedotin and bendamustine may be effective in inducing complete remission in patients ...
JUNE 13, 2017
Brentuximab Vedotin Beats Standard of Care for CTCL
The CD30-targeted antibody–drug conjugate brentuximab vedotin (BV) was far more active than current ...
MARCH 15, 2017
